Scientists test Two-Pronged attack on blood cancer
NCT ID NCT05971251
Summary
This early-stage study is testing whether adding a new drug called loncastuximab tesirine to an existing medication (acalabrutinib) is safe and effective for people with chronic lymphocytic leukemia (CLL). The main goal is to find the highest dose of the new drug that patients can safely tolerate when combined with the standard drug. The study will enroll about 24 adults with CLL who are already taking acalabrutinib but still have detectable cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.